Literature DB >> 15627613

Measurement of daughter cell accumulation during lymphocyte proliferation in vivo.

Bruce S Thompson1, Thomas C Mitchell.   

Abstract

We describe a method to characterize the effects that immunological adjuvants have on in vivo lymphocyte proliferation at the level of daughter cell accumulation. We used standard 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeling techniques to follow T cells through multiple rounds of division in experimentally treated mice and measured both the fold-increase in cell number and average number of divisions undergone by each cell. These data were then incorporated into a calculation to determine the average number of daughter cells that accumulated from each round of mitosis, termed the daughter cell accumulation index. In vivo proliferation of T cells that had been stimulated by antigen in the absence of adjuvant was associated with an index value of 1.2, far below the theoretical maximum of 2.0. Low index values indicate poor daughter cell accumulation during proliferation, either because the newly produced cells died or persisted without dividing again. Inclusion of the natural adjuvant lipopolysaccharide (LPS) led to average accumulation of 1.75 daughter cells per cell cycle and an exponential increase in peak clonal expansion. Adjuvant-induced increases in average daughter cell accumulation appeared to account for more of the enhancement in clonal expansion than did adjuvant-induced increases in the number of cell divisions undergone by each cell. Therefore measurement of changes in daughter cell accumulation can be important to understanding how adjuvants influence the yield of proliferating lymphocytes. Measurement of average daughter cell accumulation is likely to be helpful in any cellular context in which it is useful to characterize strictly mitogenic versus accumulative effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627613     DOI: 10.1016/j.jim.2004.09.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Authors:  Paula M Chilton; Thomas C Mitchell
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.

Authors:  Paula M Chilton; Diana M Hadel; Thao T To; Thomas C Mitchell; Richard P Darveau
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

3.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses.

Authors:  Irina Puliaeva; Roman Puliaev; Andrei Shustov; Mark Haas; Charles S Via
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

5.  TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Authors:  Siva K Gandhapudi; Paula M Chilton; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

6.  GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival.

Authors:  Ivo Sonderegger; Giandomenica Iezzi; Reinhard Maier; Nicole Schmitz; Michael Kurrer; Manfred Kopf
Journal:  J Exp Med       Date:  2008-09-08       Impact factor: 14.307

7.  Vaginal immunization to elicit primary T-cell activation and dissemination.

Authors:  Elena Pettini; Gennaro Prota; Annalisa Ciabattini; Alessandro Boianelli; Fabio Fiorino; Gianni Pozzi; Antonio Vicino; Donata Medaglini
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.